A Phase 1 Study of LY2874455 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced Cancer.

Trial Profile

A Phase 1 Study of LY2874455 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs LY 2874455 (Primary)
  • Indications Chronic lymphocytic leukaemia; Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly
  • Most Recent Events

    • 06 Jun 2017 Results published in the Targeted Oncology
    • 20 Apr 2016 Results of part B (n=58) of the study were presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 25 Feb 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top